NasdaqGS:SNDXBiotechs
Is Syndax (SNDX) Quietly Redefining Its R&D Focus With New Menin and EGFR Programs?
Syndax Pharmaceuticals recently held an R&D event where it outlined its late-stage programs, including revumenib and axatilimab, and introduced two new candidates: SNDX-4321, an allosteric EGFR inhibitor for EGFR-mutant NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis, with multiple IND submissions and early-stage trials planned through 2027.
A key insight is Syndax’s move to diversify beyond its two main commercial assets by licensing SNDX-4321 and advancing a...